clients, partners and patients to develop new treatments for NASH, diabetes and obesity.
Science Driven Therapeutically Focused
Delivering on the Potential of Innovative Therapeutics for Metabolic Diseases
Advise • Advance • Achieve
Clinical Development and Regulatory Strategy + State-of-the-Art Clinical Facility + Full Scope CRO Services + Global Scientific Network
Specialty consulting services for clinical development, regulatory strategy and licensing.
State-of-the-art clinical research facilities for metabolic drug and device clinical trials.
Full scope, comprehensive multi-site services to support metabolic clinical research programs.
Global network of partners connecting our clients to the most innovative research methods.
PROSCIENTO NEWS
August 6, 2018
ProSciento Expands Executive Team, Appoints Brian Mooney Chief Operating Officer Read More »
June 21, 2018
ProSciento and Tidepool Collaborate to Integrate Diabetes Device Data Aggregation Platform into Clinical Trials Read More »
SPOTLIGHT
View Our Presentation
RESEARCH COMMUNITY
March 1, 2018
Pathophysiology of Cardiovascular Disease in Diabetes Mellitus Read More »
January 19, 2018
Single Dose Euglycemic Clamp Studies Demonstrating Pharmacokinetic and Pharmacodynamic Similarity Between MK-1293 Insulin Glargine and Originator Insulin Glargine (Lantus) in Type 1 Diabetes and Healthy Subjects Read More »
December 18, 2017
FDA approves Ozempic to improve glycemic control in adults with T2D Read More »